(UTHR) United Therapeutics - Overview
Stock: Treprostinil, Orenitram, Unituxin, Aurora-GT, Xenografts
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 30.4% |
| Relative Tail Risk | -15.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.80 |
| Alpha | 28.28 |
| Character TTM | |
|---|---|
| Beta | 0.404 |
| Beta Downside | 0.392 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.00% |
| CAGR/Max DD | 0.73 |
Description: UTHR United Therapeutics December 19, 2025
United Therapeutics Corporation (NASDAQ: UTHR) is a U.S. biotech that develops and commercializes therapies for chronic, life-threatening conditions, with a primary focus on pulmonary arterial hypertension (PAH) and high-risk neuroblastoma.
Its marketed portfolio includes Tyvaso (both inhaled solution via ultrasonic nebulizer and dry-powder inhaler), the treprostinil injection Remodulin, the oral treprostinil tablet Orenitram, the PDE-5 inhibitor Adcirca, the monoclonal antibody Unituxin for neuroblastoma, and the Remunity infusion pump that delivers Remodulin.
The pipeline features RemoPro (a subcutaneous treprostinil formulation), the oral PAH candidate Ralinepag, Aurora-GT gene-therapy aimed at rebuilding pulmonary vasculature, a nebulized Tyvaso formulation for idiopathic pulmonary fibrosis, and early-stage xenograft organ products.
United Therapeutics leverages strategic collaborations: a licensing deal with DEKA for a semi-disposable subcutaneous treprostinil system, a partnership with MannKind to co-develop an inhalation powder and the Dreamboat device, and a joint development agreement with Arena Pharmaceuticals on Ralinepag.
Key financial and market indicators: FY 2023 revenue reached approximately $1.2 billion, up ~12 % YoY; cash and equivalents stood at $1.5 billion, providing runway for pipeline advancement; net income was $140 million. The global PAH market is projected to exceed $6 billion by 2028, driven by an aging population and improved diagnostic rates, while overall biotech R&D spending grew 8 % YoY, underscoring a favorable funding environment for innovative therapies.
For a deeper, data-driven valuation of UTHR, you might find ValueRay’s analyst toolkit worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 1.27b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 2.65 > 1.0 |
| NWC/Revenue: 94.22% < 20% (prev 113.5%; Δ -19.23% < -1%) |
| CFO/TA 0.21 > 3% & CFO 1.56b > Net Income 1.27b |
| Net Debt (-1.14b) to EBITDA (1.71b): -0.67 < 3 |
| Current Ratio: 6.40 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.3m) vs 12m ago -2.27% < -2% |
| Gross Margin: 88.59% > 18% (prev 0.89%; Δ 8770 % > 0.5%) |
| Asset Turnover: 43.23% > 50% (prev 38.69%; Δ 4.53% > 0%) |
| Interest Coverage Ratio: 69.07 > 6 (EBITDA TTM 1.71b / Interest Expense TTM 24.3m) |
Altman Z'' 10.00
| A: 0.40 (Total Current Assets 3.49b - Total Current Liabilities 546.3m) / Total Assets 7.35b |
| B: 1.11 (Retained Earnings 8.19b / Total Assets 7.35b) |
| C: 0.23 (EBIT TTM 1.68b / Avg Total Assets 7.24b) |
| D: 10.77 (Book Value of Equity 8.19b / Total Liabilities 760.9m) |
| Altman-Z'' Score: 19.13 = AAA |
Beneish M -3.08
| DSRI: 0.77 (Receivables 297.7m/341.8m, Revenue 3.13b/2.76b) |
| GMI: 1.00 (GM 88.59% / 88.94%) |
| AQI: 1.13 (AQ_t 0.31 / AQ_t-1 0.28) |
| SGI: 1.14 (Revenue 3.13b / 2.76b) |
| TATA: -0.04 (NI 1.27b - CFO 1.56b) / TA 7.35b) |
| Beneish M-Score: -3.08 (Cap -4..+1) = AA |
What is the price of UTHR shares?
Over the past week, the price has changed by +3.38%, over one month by -3.45%, over three months by +6.91% and over the past year by +37.20%.
Is UTHR a buy, sell or hold?
- StrongBuy: 6
- Buy: 2
- Hold: 6
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the UTHR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 530.8 | 9.4% |
| Analysts Target Price | 530.8 | 9.4% |
| ValueRay Target Price | 596 | 22.8% |
UTHR Fundamental Data Overview February 03, 2026
P/E Forward = 15.015
P/S = 6.7873
P/B = 3.0557
P/EG = 1.4347
Revenue TTM = 3.13b USD
EBIT TTM = 1.68b USD
EBITDA TTM = 1.71b USD
Long Term Debt = unknown (none)
Short Term Debt = 300.0m USD (from shortTermDebt, last fiscal year)
Debt = 300.0m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -1.14b USD (from netDebt column, last quarter)
Enterprise Value = 18.77b USD (21.23b + Debt 300.0m - CCE 2.77b)
Interest Coverage Ratio = 69.07 (Ebit TTM 1.68b / Interest Expense TTM 24.3m)
EV/FCF = 16.73x (Enterprise Value 18.77b / FCF TTM 1.12b)
FCF Yield = 5.98% (FCF TTM 1.12b / Enterprise Value 18.77b)
FCF Margin = 35.86% (FCF TTM 1.12b / Revenue TTM 3.13b)
Net Margin = 40.65% (Net Income TTM 1.27b / Revenue TTM 3.13b)
Gross Margin = 88.59% ((Revenue TTM 3.13b - Cost of Revenue TTM 356.9m) / Revenue TTM)
Gross Margin QoQ = 87.38% (prev 89.03%)
Tobins Q-Ratio = 2.55 (Enterprise Value 18.77b / Total Assets 7.35b)
Interest Expense / Debt = 1.0% (Interest Expense 3.00m / Debt 300.0m)
Taxrate = 22.67% (99.3m / 438.0m)
NOPAT = 1.30b (EBIT 1.68b * (1 - 22.67%))
Current Ratio = 6.40 (Total Current Assets 3.49b / Total Current Liabilities 546.3m)
Debt / Equity = 0.05 (Debt 300.0m / totalStockholderEquity, last quarter 6.59b)
Debt / EBITDA = -0.67 (Net Debt -1.14b / EBITDA 1.71b)
Debt / FCF = -1.01 (Net Debt -1.14b / FCF TTM 1.12b)
Total Stockholder Equity = 6.75b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.57% (Net Income 1.27b / Total Assets 7.35b)
RoE = 18.83% (Net Income TTM 1.27b / Total Stockholder Equity 6.75b)
RoCE = 24.67% (EBIT 1.68b / Capital Employed (Total Assets 7.35b - Current Liab 546.3m))
RoIC = 18.87% (NOPAT 1.30b / Invested Capital 6.88b)
WACC = 7.31% (E(21.23b)/V(21.53b) * Re(7.40%) + D(300.0m)/V(21.53b) * Rd(1.0%) * (1-Tc(0.23)))
Discount Rate = 7.40% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -2.54%
[DCF Debug] Terminal Value 83.05% ; FCFF base≈1.03b ; Y1≈1.22b ; Y5≈1.90b
Fair Price DCF = 898.3 (EV 37.54b - Net Debt -1.14b = Equity 38.68b / Shares 43.1m; r=7.31% [WACC]; 5y FCF grow 19.75% → 2.90% )
EPS Correlation: -7.53 | EPS CAGR: -46.55% | SUE: -4.0 | # QB: 0
Revenue Correlation: 98.07 | Revenue CAGR: 19.09% | SUE: -0.55 | # QB: 0
EPS next Quarter (2026-03-31): EPS=6.99 | Chg30d=-0.025 | Revisions Net=+1 | Analysts=5
EPS next Year (2026-12-31): EPS=28.59 | Chg30d=+0.102 | Revisions Net=+1 | Growth EPS=+5.9% | Growth Revenue=+5.7%